Putting Evidence Into Practice®: Evidence-Based Interventions for Chemotherapy-Induced Peripheral Neuropathy

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) continues to be a significant, debilitating symptom resulting from the administration of neurotoxic chemotherapy for the treatment of cancer. CIPN is an important consequence of cancer treatment because of its potential impact on physical functioning and quality of life. Oncology nurses play an important role in assessing, monitoring, and educating clients about CIPN. Despite investigations concerning pharmacologic and nonpharmacologic approaches to either preventing or minimizing the neurotoxicity resulting from certain chemotherapeutic agents, evidence to support the interventions is lacking. This article presents information concerning CIPN and summarizes the evidence for pharmacologic and nonpharmacologic approaches to the prevention and treatment of CIPN.

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

“…It is known that there is a significant correlation between CIPN and QOL [11][12][13][14]. In this study, as CIPN symptoms in the lower extremities become more severe, global health status and functional performance are lower and overall symptoms are severe.…”

“…The exacerbation of CIPN symptoms due to a lack of adequate CIPN-related symptom identification and early intervention can lead to dose reductions and therapy postponement or discontinuation, thus affecting therapy outcomes [8] and daily patient activities, such as enjoying pleasant events, pursuing hobbies, and sleeping, which exert negative influences on patient quality of life (QOL) [11][12][13][14]. Therefore, intensive studies are currently underway to prevent and alleviate CIPN symptoms [15][16][17][18][19], and attempts are being made to standardize CIPN assessments [20].…”

Obwodowa neuropatia wywołana chemioterapią. Część II. Zapobieganie

“…Nie opracowano bezpiecznego i skutecznego modelu postępowania w CIPN. Autorzy proponowanych algorytmów zastrzegają brak silnych dowodów opartych na zasadach medycyny opartej na faktach (evidence based medicine -EBM) i w związku z tym ograniczone możliwości wprowadzania ich w życie [9].Rozpoczynając chemioterapię, lekarz ma świadomość, że wystąpienie opisywanego zespołu jest bardzo prawdopodobne, a konsekwencją tego zdarzenia może być nawet konieczność przerwania leczenia przyczynowego. Niniejszy artykuł jest próbą przedstawienia doniesień z dostępnego piśmiennictwa dotyczących możliwości profilaktyki CIPN.…”

“…Nie opracowano bezpiecznego i skutecznego modelu postępowania w CIPN. Autorzy proponowanych algorytmów zastrzegają brak silnych dowodów opartych na zasadach medycyny opartej na faktach (evidence based medicine -EBM) i w związku z tym ograniczone możliwości wprowadzania ich w życie [9].…”

Effects of fisetin on oxaliplatin-induced neuropathic pain in mice

“…Importantly, pain is not the only symptom, and other common peripheral sensory symptoms include paresthesias and dysesthesias, numbness and tingling, and sensitivity to touch and temperature. Sometimes motor symptoms are also reported, including weakness and gait and balance disturbances (Visovsky et al, 2007). Unfortunately, this kind of neuropathic pain is only partially reversible even long after the cessation of treatment and in some rare cases damage can be permanent.…”